CN113975250A - Preparation and application of double-water-phase porous islet microcapsules with core-shell structure - Google Patents
Preparation and application of double-water-phase porous islet microcapsules with core-shell structure Download PDFInfo
- Publication number
- CN113975250A CN113975250A CN202111230390.8A CN202111230390A CN113975250A CN 113975250 A CN113975250 A CN 113975250A CN 202111230390 A CN202111230390 A CN 202111230390A CN 113975250 A CN113975250 A CN 113975250A
- Authority
- CN
- China
- Prior art keywords
- core
- phase
- porous
- microcapsule
- shell structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 75
- 239000011258 core-shell material Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000012071 phase Substances 0.000 claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000008346 aqueous phase Substances 0.000 claims abstract description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 45
- 239000000017 hydrogel Substances 0.000 claims description 23
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 239000008384 inner phase Substances 0.000 claims description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 10
- 229940072056 alginate Drugs 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000008385 outer phase Substances 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 210000004153 islets of langerhan Anatomy 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000005684 electric field Effects 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 125000004386 diacrylate group Chemical group 0.000 claims description 3
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- -1 Polydimethylsiloxane Polymers 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 238000000016 photochemical curing Methods 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000004083 survival effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 17
- 239000010410 layer Substances 0.000 description 13
- 239000004005 microsphere Substances 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012536 packaging technology Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of a double-aqueous-phase porous islet microcapsule with a core-shell structure. The internal phase is a carboxymethyl cellulose (CMC) solution. The microcapsule has good biocompatibility, target cells are added into an internal phase solution to obtain the cell-loaded microcapsule, and due to the internal liquid environment and the porous gel outside, the three-dimensional culture of the cells can be realized, the cell survival rate is improved, and the cell-loaded microcapsule can be transplanted to realize the cell treatment effect. The preparation method of the core-shell structure porous islet microcapsules based on microfluidic electrospray has the advantages of reusability, low cost, simplicity in operation, convenience, reliability and the like.
Description
Technical Field
The invention belongs to the field of biological materials, and particularly relates to a porous islet microcapsule with a core-shell structure based on microfluidic electrospray and a preparation method thereof.
Background
The common cell transplantation modes include hepatic portal vein, kidney capsule, abdominal cavity and the like, and the microcapsule is one of the cell transplantation methods capable of being transplanted into the abdominal cavity. The microcapsule is of a double-water-phase core-shell structure, the shell layer is porous hydrogel, small molecular substances can be allowed to pass through the microcapsule, and macromolecular substances such as immune cells, immune globulin and the like can be prevented, so that a certain immune isolation effect is achieved; the cellulose solution with the inner phase in liquid form provides a 3D liquid environment to enhance cell viability. The method can improve survival rate of encapsulated cells, and improve activity and effect of transplanted cells. Compared with other cell encapsulating technologies, the method has the unique advantages of being a better cell encapsulating technology and improving the effect of cell transplantation.
The traditional hydrogel packaging technology comprises a mechanical stirring method, an emulsion solvent volatilization method or a method of forming hydrogel microspheres or microcapsules by cutting an organic oil phase of a microfluidic system, most of the hydrogel microspheres or microcapsules are hydrogel solid microspheres, and the preparation method of the main structure of the hydrogel solid microspheres is complex, high in technical requirement, large in size distribution, nonuniform in particle size and poor in monodispersity. In addition, the traditional prepared microspheres and microcapsules are not beneficial to the material exchange of cells due to the solid structure, influence the growth of the cells and limit the application of the microspheres and microcapsules.
PEO is used as a pore-making agent and is mixed with alginate of an external phase, when the alginate is crosslinked with calcium ions in a collected liquid to form hydrogel, PEO does not gel and is dispersed in the hydrogel to be dissolved in water to form a porous structure in the hydrogel, and the porous structure is uniformly dispersed in the hydrogel in the order of nanometers. The size of the porous hydrogel can be adjusted by changing the concentration and the proportion of PEO, and the method is flexible and convenient.
Disclosure of Invention
In order to solve the defects of reduced cell activity, low transplantation survival rate and complex preparation of hydrogel microspheres of the traditional hydrogel-coated cells, the invention provides a double-aqueous-phase porous islet microcapsule with a core-shell structure and a preparation method thereof. In the invention, the porous islet microcapsules with the core-shell structure are designed and invented by taking ALG and PEO mixed liquor as an external phase and CMC as an internal phase, can wrap cells, realize 3D culture and can be transplanted to treat immune-related diseases.
In order to solve the technical problems, the invention adopts the technical scheme that:
a preparation method of a double-aqueous-phase porous islet microcapsule with a core-shell structure comprises the following steps:
(1) designing a microfluidic electrojet double-emulsion device:
the microfluidic electronic injection chip is prepared by adjusting the pipe diameter and the alignment mode so as to ensure that the two-phase solution can smoothly pass through the pipeline and has proper proportion;
(2) preparing an inner phase solution and an outer phase solution, and preparing the microcapsule:
the inner and outer phase solution need to have different viscosity, and the non-gel component is added into the outer phase solution; under the action of an external high-voltage electric field, the internal and external phase solutions form an immiscible core-shell structure, and the outer layer of the core-shell structure is formed into glue through ion exchange or photocuring; the above steps are repeated to prepare the microcapsule, and because the substance which does not form the gel acts as the pore-forming agent, the shell layer of the obtained microcapsule is of a porous structure, and finally the double-aqueous-phase porous islet microcapsule with the core-shell structure is prepared.
In the step (1), the microfluidic electronic injection chip is a coaxial device and can be filled with double emulsions.
The hydrogel of the outer shell is made into a porous structure by adding a pore-forming agent polyethylene oxide (PEO) solution into an alginic Acid (ALG) solution of the outer shell, and the inner phase is a solution with biocompatibility and certain viscosity, such as carboxymethyl cellulose or methyl cellulose.
The shell layer of the microcapsule is porous hydrogel, and the concentration range of the porous hydrogel is 0.5-10% w/v.
The shell layer of the microcapsule is one material or a composite of more than two materials of polyethylene oxide (PEO), polyethylene glycol (PEG), Alginate (ALG), polyethylene glycol diacrylate (PEGDA), methacrylate gelatin (GelMA), silk fibroin, hyaluronic acid, Polydimethylsiloxane (PDMS), chitosan, gelatin, lactose, galactose, dextrin, maltose, polylactic acid (PLA), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA).
Microcapsules with different sizes and core-shell proportions are obtained by adjusting the voltage electric field, the flow velocity, the collection distance and the concentration of the internal and external phase solutions; wherein an increase in voltage causes a corresponding decrease in the diameter of the microcapsules and a decrease in voltage causes a corresponding increase in the diameter of the microcapsules.
The invention also protects the double-water-phase porous islet microcapsules with the core-shell structure, which are prepared by the method, and the microcapsules have two obvious core-shell parts, wherein the shell layer of the outer phase is of a porous structure, and the core of the inner phase is of a liquid state.
Further, it contains a liquid polymer solution having a viscosity different from that of the shell layer, forming a liquid core capable of dispersing the objective cells in the internal phase.
Furthermore, the diameter of the double-water-phase porous islet microcapsule with the core-shell structure is 100-1200 mu m.
Preferably, the PEO concentration is in the range of 0.5% to 2% (w/v).
Preferably, the sodium alginate in the shell layer has a concentration of 0.5-4% (w/v), and the sodium carboxymethyl cellulose is arranged inside and is loaded with cells.
Preferably, the diameter of the double-water-phase porous islet microcapsules with the core-shell structure is 200-950 μm.
The invention also protects the application of the double-aqueous-phase porous islet microcapsules with the core-shell structure in the preparation of the transplantable cell-loaded microcapsules for realizing the cell therapy effect.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention prepares the microcapsule with a core-shell structure by a microfluidic electrospray technology, the shell layer is hydrogel, the core layer is liquid, the method is simple, the operation is convenient, the price is low, the repeatability is high, the high technical requirement is not needed, and the size of the microcapsule is easy to control.
(2) The invention designs a porous islet microcapsule with a core-shell structure, wherein a non-gelling component is added into a shell layer to obtain a microcapsule shell with a porous structure, so that macromolecular substances such as immune cells, immune globulin and the like are isolated while exchange of small molecular substances is allowed.
(3) The aqueous two-phase porous islet microcapsules with the core-shell structure can be used for cell 3D culture, cell wrapping transplantation, tissue engineering and the like.
Drawings
FIG. 1 is a schematic diagram of a preparation process of porous islet microcapsules with a core-shell structure; the outer phase is a mixed solution of alginate and PEO, the inner phase is a carboxymethyl cellulose solution, a high-voltage electric field is applied to the outside, and the collection solution is a calcium chloride solution.
In the process of forming the porous islet microcapsules with the core-shell structure shown in fig. 2, the two-phase solution can be clearly seen to form an inner phase and an outer phase, so that the microcapsules with the core-shell structure are obtained.
FIG. 3 is a light and electron microscope image of the porous islet microcapsules with core-shell structure obtained in one example; wherein, the drawing a is a forming process drawing, the drawing b is a light mirror drawing, and the drawings c-d are electron microscope drawings.
Figure 4 effect of several key factors on microcapsule diameter.
Detailed Description
The above-mentioned contents of the present invention are further described in detail by way of examples below, but it should not be understood that the scope of the above-mentioned subject matter of the present invention is limited to the following examples, and any technique realized based on the above-mentioned contents of the present invention falls within the scope of the present invention.
The experimental procedures used in the examples below are conventional procedures unless otherwise specified, and the reagents, methods and equipment used therein are conventional in the art unless otherwise specified.
Example 1
Preparation of porous islet microcapsules with core-shell structure
(1) Designing a microfluidic chip:
firstly, designing a microfluidic electronic injection chip, selecting a capillary glass tube with the diameter of 800 micrometers and 300 micrometers, adjusting the outlet of an external phase capillary tube to be 500 micrometers by drawing the tube, nesting the capillary tubes with two diameters into a capillary tube with a coaxial outlet by adopting a coaxial method, sticking and fixing the capillary tube with the coaxial outlet at a corresponding position by using a needle head, and reserving an inlet of a two-phase solution. As shown in fig. 1. And repeatedly washing with ultrapure water to obtain the microfluidic chip.
(2) Preparing a core-shell structure porous islet microcapsule:
in order to enable the shell layer hydrogel to have a porous structure, preparing 1% (w/v) sodium alginate solution, adding a small amount of 1% (w/v) PEO solution, and stirring overnight to fully and uniformly mix the two solutions; preparing 1% (w/v) sodium carboxymethylcellulose solution, building a microfluidic electronic injection platform comprising a high-voltage direct-current power supply and two flow pumps, and finally setting and adjusting flow and voltage to obtain the porous islet microcapsules with the core-shell structure, as shown in fig. 2.
Example 2
Preparation of porous islet microcapsules with core-shell structure
(1) Designing a microfluidic chip:
firstly, designing a microfluidic electronic injection chip, selecting a capillary glass tube with the diameter of 800 micrometers and 300 micrometers, adjusting the outlet of an external phase capillary tube to be 500 micrometers by drawing the tube, nesting the capillary tubes with two diameters into a capillary tube with a coaxial outlet by adopting a coaxial method, sticking and fixing the capillary tube with the coaxial outlet at a corresponding position by using a needle head, and reserving an inlet of a two-phase solution. As shown in fig. 1. And repeatedly washing with ultrapure water to obtain the microfluidic chip.
(2) Preparing a core-shell structure porous islet microcapsule:
in order to enable the shell layer hydrogel to have a porous structure, polyethylene glycol diacrylate (PEGDA) solutions with different concentration ranges are prepared, a small amount of 1% (w/v) PEO solution is added, and the mixture is stirred overnight to fully and uniformly mix the two solutions; preparing 1% (w/v) sodium carboxymethylcellulose solution, building a microfluidic electronic injection platform comprising a high-voltage direct-current power supply and two flow pumps, and finally setting and adjusting flow and voltage to obtain the porous islet microcapsules with the core-shell structure, as shown in fig. 2.
Example 3
Preparation of porous islet microcapsules with core-shell structure
(1) Designing a microfluidic chip:
firstly, designing a microfluidic electronic injection chip, selecting a capillary glass tube with the diameter of 800 micrometers and 300 micrometers, adjusting the outlet of an external phase capillary tube to be 500 micrometers by drawing the tube, nesting the capillary tubes with two diameters into a capillary tube with a coaxial outlet by adopting a coaxial method, sticking and fixing the capillary tube with the coaxial outlet at a corresponding position by using a needle head, and reserving an inlet of a two-phase solution. As shown in fig. 1. And repeatedly washing with ultrapure water to obtain the microfluidic chip.
(2) Preparation of core-shell structure porous islet microcapsules
In order to enable the shell layer hydrogel to have a porous structure, methacrylate gelatin (GelMA) solutions with different concentrations are prepared, a small amount of 1% (w/v) PEO solution is added, and the mixture is stirred overnight to fully and uniformly mix the two solutions; preparing 1% (w/v) sodium carboxymethylcellulose solution, building a microfluidic electronic injection platform comprising a high-voltage direct-current power supply and two flow pumps, and finally setting and adjusting flow and voltage to obtain the porous islet microcapsules with the core-shell structure, as shown in fig. 2.
Adding a small amount of 1% (w/v) PEO solution into 1% (w/v) sodium alginate solution to serve as an external phase; 1% (w/v) sodium carboxymethylcellulose solution and islet cells are used as internal phases, a microfluidic electrospray platform is built to prepare the porous islet microcapsules with good monodispersity and a core-shell structure, and the experimental results show that the islet cells can grow well in the microcapsules, the survival rate is more than 90%, and the islet cells have the effect of reducing the blood sugar of a mouse after being transplanted into a diabetic mouse.
The above description is only a preferred embodiment of the present invention, and should not be taken as limiting the invention in any way, and any person skilled in the art can make any simple modification, equivalent replacement, and improvement on the above embodiment without departing from the technical spirit of the present invention, and still fall within the protection scope of the technical solution of the present invention.
Claims (10)
1. A preparation method of a double-aqueous-phase porous islet microcapsule with a core-shell structure is characterized by comprising the following steps:
(1) designing a microfluidic electrojet double-emulsion device:
the microfluidic electronic injection chip is prepared by adjusting the pipe diameter and the alignment mode so as to ensure that the two-phase solution can smoothly pass through the pipeline and has proper proportion;
(2) preparing an inner phase solution and an outer phase solution, and preparing the microcapsule:
the inner and outer phase solution need to have different viscosity, and the non-gel component is added into the outer phase solution; under the action of an external high-voltage electric field, the internal and external phase solutions form an immiscible core-shell structure, and the outer layer of the core-shell structure is formed into glue through ion exchange or photocuring; the above steps are repeated to prepare the microcapsule, and because the substance which does not form the gel acts as the pore-forming agent, the shell layer of the obtained microcapsule is of a porous structure, and finally the double-aqueous-phase porous islet microcapsule with the core-shell structure is prepared.
2. The preparation method of the aqueous two-phase porous pancreatic islet microcapsule with the core-shell structure according to claim 1, is characterized in that: in the step (1), the microfluidic electronic injection chip is a coaxial device and can be filled with double emulsions.
3. The preparation method of the aqueous two-phase porous pancreatic islet microcapsule with the core-shell structure according to claim 1, is characterized in that: the hydrogel of the outer shell is made into a porous structure by adding a pore-forming agent polyethylene oxide (PEO) solution into an alginic Acid (ALG) solution of the outer shell, and the inner phase is a solution with biocompatibility and certain viscosity, such as carboxymethyl cellulose or methyl cellulose.
4. The preparation method of the aqueous two-phase porous pancreatic islet microcapsule with the core-shell structure according to claim 3, is characterized in that: the shell layer of the microcapsule is porous hydrogel, and the concentration range of the porous hydrogel is 0.5-10% w/v.
5. The preparation method of the aqueous two-phase porous pancreatic islet microcapsule with the core-shell structure according to claim 3, is characterized in that: the shell layer of the microcapsule is one material or a composite of more than two materials of polyethylene oxide (PEO), polyethylene glycol (PEG), Alginate (ALG), polyethylene glycol diacrylate (PEGDA), methacrylate gelatin (GelMA), silk fibroin, hyaluronic acid, Polydimethylsiloxane (PDMS), chitosan, gelatin, lactose, galactose, dextrin, maltose, polylactic acid (PLA), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA).
6. The preparation method of the aqueous two-phase porous pancreatic islet microcapsule with the core-shell structure according to claim 1, is characterized in that: microcapsules with different sizes and core-shell proportions are obtained by adjusting the voltage electric field, the flow velocity, the collection distance and the concentration of the internal and external phase solutions; wherein an increase in voltage causes a corresponding decrease in the diameter of the microcapsules and a decrease in voltage causes a corresponding increase in the diameter of the microcapsules.
7. The aqueous two-phase porous islet microcapsules with a core-shell structure, prepared by the method of any one of claims 1 to 6, is characterized in that: the composite material has two obvious core-shell parts, the shell layer of the outer phase is in a porous structure, and the core of the inner phase is in a liquid state.
8. The aqueous two-phase porous islet microcapsules with core-shell structure according to claim 7, characterized in that: the polymer solution in liquid state has viscosity different from that of the shell layer, forms a liquid core, and can disperse the target cells in the inner phase.
9. The aqueous two-phase porous islet microcapsules with core-shell structure according to claim 7, characterized in that: the diameter of the double-water-phase porous islet microcapsule with the core-shell structure is 100-1200 mu m.
10. The use of the aqueous two-phase porous islet microcapsules with a core-shell structure according to claim 7 for the preparation of implantable cell-loaded microcapsules for the realization of a cell therapeutic effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111230390.8A CN113975250A (en) | 2021-10-22 | 2021-10-22 | Preparation and application of double-water-phase porous islet microcapsules with core-shell structure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111230390.8A CN113975250A (en) | 2021-10-22 | 2021-10-22 | Preparation and application of double-water-phase porous islet microcapsules with core-shell structure |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113975250A true CN113975250A (en) | 2022-01-28 |
Family
ID=79740117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111230390.8A Pending CN113975250A (en) | 2021-10-22 | 2021-10-22 | Preparation and application of double-water-phase porous islet microcapsules with core-shell structure |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113975250A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115138305A (en) * | 2022-06-30 | 2022-10-04 | 成都世联康健生物科技有限公司 | Preparation method and device of GelMA-alginate core-shell microcapsule and core-shell microcapsule |
CN115212813A (en) * | 2022-07-19 | 2022-10-21 | 西南交通大学 | Full-aqueous phase double-layer porous gel microsphere and preparation method and application thereof |
CN115322982A (en) * | 2022-08-15 | 2022-11-11 | 北京工商大学 | Preparation method and application of cell-loaded microcapsule |
CN115429818A (en) * | 2022-10-21 | 2022-12-06 | 东南大学 | Preparation method of porous mesenchymal stem cell composite islet microgel |
CN118109451A (en) * | 2024-04-30 | 2024-05-31 | 南京师范大学 | Method for high-throughput screening of microbial strains based on electrospray technology and application |
RU2822875C1 (en) * | 2023-12-25 | 2024-07-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации | Method for preparing microcapsules with langerhans islets and microcapsule according to disclosed method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120070878A1 (en) * | 2010-09-22 | 2012-03-22 | Fink Katherine A | Microporous Microfluidic Device |
CN106947019A (en) * | 2017-03-27 | 2017-07-14 | 上海小海龟科技有限公司 | The preparation method and device of a kind of hydrogel microsphere |
CN208944127U (en) * | 2018-09-20 | 2019-06-07 | 中国科学技术大学 | A kind of centrifugal microfluidic control device |
US20200038869A1 (en) * | 2016-10-07 | 2020-02-06 | University Of Maryland, College Park | Integration of Porous Monolithic Structures Within Microfluidic Systems |
CN111500523A (en) * | 2020-04-17 | 2020-08-07 | 南京鼓楼医院 | Preparation method of biomass core-shell structure cell microcarrier |
CN111875817A (en) * | 2020-03-20 | 2020-11-03 | 江苏普瑞康生物医药科技有限公司 | Preparation method and application of hollow microspheres |
-
2021
- 2021-10-22 CN CN202111230390.8A patent/CN113975250A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120070878A1 (en) * | 2010-09-22 | 2012-03-22 | Fink Katherine A | Microporous Microfluidic Device |
US20200038869A1 (en) * | 2016-10-07 | 2020-02-06 | University Of Maryland, College Park | Integration of Porous Monolithic Structures Within Microfluidic Systems |
CN106947019A (en) * | 2017-03-27 | 2017-07-14 | 上海小海龟科技有限公司 | The preparation method and device of a kind of hydrogel microsphere |
CN208944127U (en) * | 2018-09-20 | 2019-06-07 | 中国科学技术大学 | A kind of centrifugal microfluidic control device |
CN111875817A (en) * | 2020-03-20 | 2020-11-03 | 江苏普瑞康生物医药科技有限公司 | Preparation method and application of hollow microspheres |
CN111500523A (en) * | 2020-04-17 | 2020-08-07 | 南京鼓楼医院 | Preparation method of biomass core-shell structure cell microcarrier |
Non-Patent Citations (2)
Title |
---|
王化平等主编, 徐州:中国矿业大学出版社 * |
裘炳毅等主编: "《现代化妆品科学与技术 上》", 31 March 2016, 中国轻工业出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115138305A (en) * | 2022-06-30 | 2022-10-04 | 成都世联康健生物科技有限公司 | Preparation method and device of GelMA-alginate core-shell microcapsule and core-shell microcapsule |
CN115212813A (en) * | 2022-07-19 | 2022-10-21 | 西南交通大学 | Full-aqueous phase double-layer porous gel microsphere and preparation method and application thereof |
CN115322982A (en) * | 2022-08-15 | 2022-11-11 | 北京工商大学 | Preparation method and application of cell-loaded microcapsule |
CN115322982B (en) * | 2022-08-15 | 2023-08-15 | 北京工商大学 | Preparation method and application of cell-loaded microcapsule |
CN115429818A (en) * | 2022-10-21 | 2022-12-06 | 东南大学 | Preparation method of porous mesenchymal stem cell composite islet microgel |
RU2822875C1 (en) * | 2023-12-25 | 2024-07-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации | Method for preparing microcapsules with langerhans islets and microcapsule according to disclosed method |
CN118109451A (en) * | 2024-04-30 | 2024-05-31 | 南京师范大学 | Method for high-throughput screening of microbial strains based on electrospray technology and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113975250A (en) | Preparation and application of double-water-phase porous islet microcapsules with core-shell structure | |
Yang et al. | Biomass microcapsules with stem cell encapsulation for bone repair | |
CN105641743B (en) | A kind of micro fluidic device and the method for preparing microgel using the device | |
Liu et al. | Preparation of monodisperse calcium alginate microcapsules via internal gelation in microfluidic-generated double emulsions | |
WO2019091145A1 (en) | Microfluidic controlling technology for single-step, continuous preparation of calcium alginate microgel | |
CN108524455B (en) | Preparation method and application of pH-responsive calcium alginate/vaterite calcium carbonate composite microspheres with controllable release rate | |
US6023009A (en) | Artificial pancreas | |
CN109701461A (en) | A kind of preparation and its application of the calcium carbonate based on PEG/Dex aqueous two-phase/calcium alginate compounded micro-capsule | |
JP2002538194A (en) | Cell-protecting biocompatible encapsulation system for bioactive substances and method for producing the same | |
CN106589412B (en) | A kind of preparation method of the polymer microgel based on microflow control technique | |
Zhang et al. | Preparation of single, heteromorphic microspheres, and their progress for medical applications | |
Khanmohammadi et al. | Cell encapsulation in core-shell microcapsules through coaxial electrospinning system and horseradish peroxidase-catalyzed crosslinking | |
CN109897387A (en) | Application, porous gel and its preparation of a kind of modified gelatin in water packet air lotion | |
CN106470666A (en) | Microcapsule encapsulation technology and products thereof | |
CN112641755B (en) | Method for preparing colon-targeted microcapsule by applying microfluidics technology | |
CN114796617B (en) | Composite 3D printing ink and application thereof | |
CN205549077U (en) | A micro -fluidic device for preparing microgel | |
CN103980519B (en) | A kind of preparation method of Magnetic Agarose sugar microsphere | |
Liu et al. | Aqueous two-phase emulsions-templated tailorable porous alginate beads for 3D cell culture | |
CN111330072B (en) | Preparation method and application of bionic porous MSCs microspheres | |
CN111195371A (en) | Micro-heterotype cell-carrying alginic acid gel and preparation method and application thereof | |
JPS59205985A (en) | Recovery of non-secretory substance produced from cell | |
WO2012099482A2 (en) | Device, method and system for preparing microcapsules | |
JPH07507810A (en) | implantable capsule | |
CN106267164A (en) | Single dispersing insulin/chitosan gel rubber microsphere of size tunable and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220128 |